Researchers have combined artificial intelligence with genome-wide CRISPR screening to uncover a surprising new drug target for psoriasis: the oxytocin receptor, best known for its role in childbirth and social bonding. In mouse studies, topical gels blocking the oxytocin receptor reduced psoriasis-related inflammation as effectively as a commonly used injected biologic. The study also identified another promising target, ALOX5, opening the door to new skin-specific treatments that may avoid the widespread immune suppression associated with current therapies. This AI-guided approach could accelerate the discovery of safer, more effective treatments for psoriasis and many other inflammatory diseases.
Read more at MedicalXpress